Key result
Surgery for viable LV aneurysm is linked to ~87% lower annual cardiac mortality versus medical therapy.
Why the study?
The prognostic value of myocardial viability assessment on left ventricular aneurysms in ischemic cardiomyopathy patients remains undetermined.
Does surgical treatment improve survival compared to medical therapy in patients with viable and nonviable LV aneurysms?
Cohort (n=70)
Does surgical treatment improve survival compared to medical therapy in patients with viable and nonviable LV aneurysms?
In patients with ischemic cardiomyopathy and LV aneurysms, the presence of viable aneurysmal tissue predicts higher mortality with medical therapy, which is significantly improved by surgical revascularization.
Answers are grounded in this paper and cite their sources.
Supports surgery consideration in viable LV aneurysm; hypothesis-generating and leaves open nonviable cases plus need for RCTs.
UNLABELLED: The prognostic value of myocardial viability assessment on left ventricular (LV) aneurysms remains undetermined. We aimed, first, to evaluate the long-term survival benefit of assessing the viability of the aneurysmal myocardium in patients with ischemic cardiomyopathy and, second, in the revascularization subgroup, to compare the short-term effects on LV function and clinical symptoms in patients treated by revascularization alone or by revascularization plus aneurysmectomy. METHODS: Seventy consecutive patients with an LV aneurysm who underwent 99mTc-sestamibi SPECT and 18F-FDG PET were followed up for a median of 6.8 y (range, 0.1-8.8 y). Only cardiac death during follow-up served as the endpoint. Patients were classified into 4 groups by aneurysmal viability and by treatment strategy (medical or surgical). Further, the effects of aneurysmectomy on LV function at 3 mo were evaluated by an analysis of revascularized patients grouped by aneurysmal viability and by aneurysmectomy. RESULTS: Twenty-four patients were assigned to medical therapy, and 46 patients were assigned to surgery (18 revascularization alone and 28 revascularization plus aneurysmectomy). The annual cardiac mortality rate in patients with a viable aneurysm treated medically (n = 10) was significantly higher than that in patients with a viable aneurysm treated surgically (n = 23) (11.6% vs. 1.5%, chi2 = 12.87, P < 0.0001) and was also significant higher than that in patients with a nonviable aneurysm treated medically (n = 14) (chi2 = 4.13, P < 0.05) or surgically (n = 23) (chi2 = 10.46, P = 0.001). Multivariate analysis showed that the aneurysmal mismatch score (P = 0.003) and surgical therapy (P = 0.001) were independent predictors of cardiac death. Improvement of LV function and symptoms after revascularization (P < 0.05) was observed in patients with revascularization plus aneurysmectomy and in patients with a viable aneurysm and revascularization only. CONCLUSION: Viability in LV aneurysm in patients with ischemic cardiomyopathy was a negative independent predictor of survival. Compared with medical therapy, coronary revascularization was associated with improved long-term survival, symptoms, and LV function in patients with a viable aneurysm. These findings warrant further prospective investigations.
No takes yet. Share an insight, caveat, or question.
Zhang et al. (2008) conducted a cohort in Ischemic cardiomyopathy with left ventricular aneurysm (n=70). Surgical treatment (revascularization with or without aneurysmectomy) vs. Medical therapy was evaluated on Cardiac death (p=<0.0001). In patients with a viable LV aneurysm, surgical treatment was associated with a lower annual cardiac mortality rate compared to medical therapy.
Synapse has enriched 10 related papers. Consider them for comparative context: